These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29534661)

  • 1. Management of Plasma Cell-Rich Acute Rejection in Living-Related Kidney Transplant: Role of Proteasome Inhibitor.
    Abbas K; Mubarak M; Zafar MN; Musharraf W; Imam M; Aziz T; Rizvi AH
    Exp Clin Transplant; 2019 Feb; 17(1):42-46. PubMed ID: 29534661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib Eliminates Plasma Cells From a Renal Graft in Plasma Cell-Rich Acute Rejection.
    Tasaki M; Saito K; Nakagawa Y; Ikeda M; Imai N; Ito Y; Sudo M; Ikezumi Y; Yamada T; Hasegawa H; Kobayashi T; Miura K; Narita I; Takahashi K; Tomita Y
    Transplant Proc; 2019; 51(6):1732-1738. PubMed ID: 31301858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection.
    Lichvar AB; Tremblay S; Leino AD; Shields AR; Cardi MA; Abu Jawdeh BG; Govil A; Kremer J; Cuffy M; Paterno F; Diwan T; Brailey P; Girnita A; Alloway RR; Woodle ES
    Transplantation; 2020 Nov; 104(11):2403-2414. PubMed ID: 32000256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
    Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
    Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
    Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis.
    Wan SS; Ying TD; Wyburn K; Roberts DM; Wyld M; Chadban SJ
    Transplantation; 2018 Apr; 102(4):557-568. PubMed ID: 29315141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological features and outcomes of kidney allografts in plasma cell-rich acute rejection: A case series.
    Hamada AM; Yamamoto I; Kawabe M; Katsumata H; Yamakawa T; Katsuma A; Nakada Y; Kobayashi A; Koike Y; Miki J; Yamada H; Kimura T; Tanno Y; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
    Nephrology (Carlton); 2018 Jul; 23 Suppl 2():22-26. PubMed ID: 29968414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
    Trials; 2014 Apr; 15():107. PubMed ID: 24708575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.
    Pearl MH; Nayak AB; Ettenger RB; Puliyanda D; Palma Diaz MF; Zhang Q; Reed EF; Tsai EW
    Pediatr Nephrol; 2016 Aug; 31(8):1341-8. PubMed ID: 27048228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A suspected case of plasma cell-rich acute renal transplant rejection associated with de novo donor-specific antibody.
    Yoshikawa M; Kitamura K; Ishimura T; Hara S; Fujisawa M; Nishi S
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():66-9. PubMed ID: 26031590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Incidence of Paralytic Ileus After Bortezomib Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients: Report of 2 Cases.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Cid J; Lozano M; Campistol JM; Oppenheimer F
    Transplantation; 2015 Nov; 99(11):e170-1. PubMed ID: 26492053
    [No Abstract]   [Full Text] [Related]  

  • 14. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
    Eskandary F; Regele H; Baumann L; Bond G; Kozakowski N; Wahrmann M; Hidalgo LG; Haslacher H; Kaltenecker CC; Aretin MB; Oberbauer R; Posch M; Staudenherz A; Handisurya A; Reeve J; Halloran PF; Böhmig GA
    J Am Soc Nephrol; 2018 Feb; 29(2):591-605. PubMed ID: 29242250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subclinical antibody-mediated rejection due to anti-human-leukocyte-antigen-DR53 antibody accompanied by plasma cell-rich acute rejection in a patient with cadaveric kidney transplantation.
    Katsuma A; Yamamoto I; Komatsuzaki Y; Niikura T; Kawabe M; Okabayashi Y; Yamakawa T; Katsumata H; Nakada Y; Kobayashi A; Tanno Y; Miki J; Yamada H; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():31-4. PubMed ID: 26971538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of acute antibody-mediated rejection using bortezomib: a case report.
    Sin YH; Kim YJ; Oh JS; Lee JH; Kim SM; Kim JK
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():86-9. PubMed ID: 26031595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
    Ruangkanchanasetr P; Satirapoj B; Termmathurapoj S; Namkhanisorn K; Suaywan K; Nimkietkajorn V; Luesutthiviboon L
    Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Borderline Changes on Dysfunctional Renal Allograft Biopsies: Clinical Relevance in a Living Related Renal Transplant Setting.
    Mubarak M; Shakeel S; Abbas K; Aziz T; Zafar MN; Naqvi SA; Rizvi SA
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):24-27. PubMed ID: 28260426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with a bortezomib-based regimen.
    Nigos JG; Arora S; Nath P; Hussain SM; Marcus RJ; Ko TY; Sureshkumar KK
    Exp Clin Transplant; 2012 Dec; 10(6):609-13. PubMed ID: 23216567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.